Image

HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)

HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)

Recruiting
18 years and older
All
Phase 1/2

Powered by AI

Overview

Study of HS235 in Obese Participants with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

Description

A Phase 1b/2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Obese Participants with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

Eligibility

Inclusion Criteria:

Participants are eligible to be included in the study only if they meet at least all the following criteria:

  1. Male or female, ≥ 18 years of age.
  2. \[Sub-population A only - using a remote PAP sensor\]- Ambulatory PAP monitoring (e.g., CardioMEMS™ HF System or Cordella™ HF System) implanted in the course of standard of care at least 90 days before Screening.

    Hemodynamic evidence of PH with:

    1. mPAP ≥ 25 mm Hg, as measured in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization AND,
    2. dPAP ≥ 15 mm Hg, as measured in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization.
  3. \[Sub-population B only - without a remote PAP sensor\]

    Hemodynamic evidence of PH based on the presence of all the following RHC parameters obtained during the Screening period, prior to randomization:

    1. PVR ≥ 240 dyn\*sec/cm5 or ≥ 3 WU, and
    2. mPAP \> 20 mmHg, and
    3. PAWP \> 15 mmHg but \< 30 mmHg, and
    4. dPAP ≥ 15 mmHg.
  4. Established diagnosis of HFpEF with left ventricular ejection fraction (LVEF) ≥ 45 % as measured by echocardiography during Screening and and no documented LVEF \< 45% during the 2 years preceding Screening..
  5. New York Heart Association (NYHA) class II or III heart failure symptoms.
  6. Stable diuretic regimen during the screening period.
  7. Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) \< 90 at screening.
  8. 6-minute walking distance (6MWD) ≥ 100 m at screening.
  9. Body mass index ≥ 30 to ≤ 50 kg/m2 and Body weight ≤140 kg.
  10. Ability to adhere to study visit schedule and understand and comply with all protocol requirements.

Exclusion Criteria:

  1. Hospitalization for any worsening medical condition or major surgery within 4 weeks prior to screening.
  2. Occurrence of an acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within 90 days prior to Screening.
  3. Implantation of a cardiac resynchronization therapy (CRT) device within 90 days before screening.
  4. Planned cardiovascular revascularization or planned implantation of CRT device.
  5. History of heart transplant or on heart transplant list.
  6. History of serious or life-threatening cardiac arrhythmia within 90 days prior to screening.
  7. Systemic hypotension or uncontrolled systemic hypertension.
  8. History of Pericardial constriction or hypertrophic cardiomyopathy.
  9. History of significant valvular stenosis or regurgitation.
  10. Participants with a pneumonectomy or more than moderate Chronic Obstructive Pulmonary Disease (COPD) or mild interstitial lung disease (ILD) or mild obstructive sleep apnea (OSA).

Study details
    Pulmonary Hypertension
    Heart Failure With Preserved Ejection Fraction

NCT07123779

35Pharma Inc

22 August 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.